|Articles|July 31, 2017

Study Finds Correlations Between Intestinal Viruses & Risk of Type 1 Diabetes

Researchers from Washington University, in St. Louis, find correlations between specific groups of intestinal viruses and the risk of type 1 diabetes.

New research coming in from Washington University, in St. Louis, has found correlations between specific groups of viruses and the risk of type 1 diabetes (T1D).

In fact, these viruses within a child’s intestines can offer insight into the likelihood of that child eventually developing the disease. Essentially, it all depends on the diversity of the child’s intestinal viromes: the less diverse they are, the more likely the child is to be diagnosed with T1D, according to the study published in PNAS.

“We identified one virus that was significantly associated with reduced risk, and another group of viruses that was associated with increased risk of developing antibodies against the children’s own cells,” said Herbert “Skip” Virgin IV, MD, PhD, a professor and head of pathology and immunology at the university. “It looks like the balance of these two groups of viruses may control the risk of developing the antibodies that can lead to type 1 diabetes.”

The implications of these research findings is potentially significant due to the fact that doctors currently do not have a way to accurately predict which children are at the highest risk for T1D, aside from considering genetic risk factors.

According to the Juvenile Diabetes Research Foundation, about 40,000 US children are diagnosed with T1D each year.

In hopes of getting a better understanding of T1D risk, the researchers collected 220 virus-enriched preparations from fecal samples taken from 22 children who had genetic risk factors for developing T1D. Of those children, half had developed the autoantibodies associated with the inhibition of insulin production, and 5 of those 11 were diagnosed with clinical T1D. The other children in the study had genetic risk factors, but did not develop the T1D-associated autoantibodies.

By analyzing the fecal samples, researchers were able to draw distinctions between the viromes of children with T1D and those who did not get the disease despite their higher genetic risk profiles. The team also found a previously unidentified circovirus that appears to have a negative correlation with T1D risk. Five of the 11 children who did not develop the autoantibodies had the circovirus in their fecal samples, but none of the 11 children with the antibodies carried the virus.

Guoyan Zhao, PhD, an assistant professor of pathology and immunology at Washington University, said this could mark the first time a circovirus has been linked to a disease in humans.

“Circoviruses have never been associated with disease in people,” said Zhao, in a press release. “Multiple lines of evidence support the inverse association between the virus we found and the development of autoantibodies. This suggests that having a circovirus may be a good thing for people at high risk for diabetes.”

Conversely, the researchers found that children whose viromes contained bacteriophages that target Bacteroides—a group of intestinal bacteria—were at a higher risk of developing T1D.

“Previous studies had found that changes in Bacteroides species are associated with developing type 1 diabetes, and here we found that viruses that infect Bacteroides are associated with the development of auto-antibodies,” Dr. Virgin said. “Our findings support the idea that Bacteroides or other bacteria, and the viruses that infect them, play a role in the pathological process that leads to diabetes.”

The Washington University study follows a 2015 study in Finland which looked at the gut microbiomes of children with high T1D risk and found similar correlations between bacteria profiles and the likelihood of developing T1D.

Dr. Virgin hopes his research and will not only lead to better prediction of T1D, but also eventually to prevention of the disease.

“There’s a lot of verification that needs to be done,” Dr. Virgin said. “We need to see if we can replicate these findings in another group of children, and then we have to show causality in an animal model. But if these results hold up, we may one day be able to prevent type 1 diabetes by treating high-risk children with circoviruses. It can be a terrible disease and no one knows how to prevent it. Circoviruses are worth investigating.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.